Background: Patients with a single hepatocellular carcinoma (HCC) ≤3 cm and preserved liver function have the highest likelihood to be cured if treated. The most adequate treatment methods are yet a matter that is debated. Methods: We reviewed the literature about open anatomic resection (AR), laparoscopic liver resection (LLR), and percutaneous thermal ablation (PTA). Results: PTA is effective as resection for HCC < 2 cm, when they are neither subcapsular nor perivascular. PTA in HCC of 2–3 cm is under evaluation. AR with the removal of the tumor-bearing portal territory is recommended for HCC > 2 cm, except for subcapsular ones. In comparison with open surgery, LRR has better short-term outcomes and non-inferior long-term outcomes. LLR is standardized for superficial limited resections and for left-sided AR. Conclusions: According to the available evidences, the following therapeutic proposal can be advanced. Laparoscopic limited resection is the standard for any subcapsular HCC. PTA is the first-line treatment for deep-located HCC < 2 cm, except for those in contact with Glissonean pedicles. Laparoscopic AR is the standard for deep-located HCC of 2–3 cm of the left liver, while open AR is the standard for deep-located HCC of 2–3 cm in the right liver. HCC in contact with Glissonean pedicles should be scheduled for resection (open or laparoscopic) independent of their size. Liver transplantation is reserved to otherwise untreatable patients or as a salvage procedure at recurrence.

Keywords:
Hepatocellular carcinoma, Open liver resection, Laparoscopic liver resection, Anatomic liver resection, Percutaneous thermal ablation, Percutaneous radiofrequency ablation
1.
El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118–1127.
2.
Ioannou GN, Green PK, Berry K: HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017:pii:S0168-8278(17)32273-0.
3.
Viganò L, Conci S, Cescon M, et al: Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol 2015; 63: 93–101.
4.
Torzilli G, Belghiti J, Kokudo N, et al: A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg 2013; 257: 929–937.
5.
Livraghi T, Meloni F, Di Stasi M, et al: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47: 82–89.
6.
Cherqui D, Laurent A, Mocellin N, et al: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250: 738–746.
7.
Sogawa H, Shrager B, Jibara G, et al: Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. HPB 2013; 15: 134–141.
8.
Spolverato G, Vitale A, Ejaz A, et al: The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg 2015; 39: 1474–1484.
9.
Nakashima T, Kojiro M: Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis 1986; 6: 259–266.
10.
Makuuchi M, Hasegawa H, Yamazaki S: Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 1985; 161: 346–350.
11.
Ciria R, Cherqui D, Geller DA, et al: Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing. Ann Surg 2016; 263: 761–777.
12.
Wood BJ, Kruecker J, Abi-Jaoudeh N, et al: Navigation systems for ablation. J Vasc Interv Radiol 2010; 21:S257–S263.
13.
Leung U, Kuk D, D’Angelica MI, Kingham TP, et al: Long-term outcomes following microwave ablation for liver malignancies. Br J Surg 2015; 102: 85–91.
14.
Fan ST, Lo CM, Liu CL, et al: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322–330.
15.
Torzilli G, Makuuchi M, Inoue K, et al: No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999; 134: 984–992.
16.
Imamura H, Seyama Y, Kokudo N, et al: One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198–1206.
17.
Cescon M, Cucchetti A, Grazi GL, et al: Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables. Arch Surg 2009; 144: 57–63.
18.
Donadon M, Costa G, Cimino M, et al: Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score. World J Surg 2015; 39: 237–243.
19.
Donadon M, Fontana A, Palmisano A, et al: Individualized risk estimation for postoperative morbidity after hepatectomy: the Humanitas score. HPB 2017; 19: 910–918.
20.
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
22.
Cucchetti A, Cescon M, Ercolani G, et al: A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 3697–3705.
23.
Eguchi S, Kanematsu T, Arii S, et al: Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008; 143: 469–475.
24.
Tanaka K, Shimada H, Matsumoto C, et al: Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery 2008; 143: 607–615.
25.
Wakai T, Shirai Y, Sakata J, et al: Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 2007; 14: 1356–1365.
26.
Hasegawa K, Kokudo N, Imamura H, et al: Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005; 242: 252–259.
27.
Regimbeau JM, Kianmanesh R, Farges O, et al: Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery 2002; 131: 311–317.
28.
Shindoh J, Makuuchi M, Matsuyama Y, et al: Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol 2016; 64: 594–600.
29.
Ishii M, Mizuguchi T, Kawamoto M, et al: Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma. World J Gastroenterol 2014; 20: 3335–3342.
30.
Cucchetti A, Qiao GL, Cescon M, et al: Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma. Surgery 2014; 155: 512–521.
31.
Hirokawa F, Kubo S, Nagano H, et al: Do patients with small solitary hepatocellular carcinomas without macroscopically vascular invasion require anatomic resection? Propensity score analysis. Surgery 2015; 157: 27–36.
32.
Okamura Y, Ito T, Sugiura T, et al: Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma: a case-controlled study with propensity score matching. J Gastrointest Surg 2014; 18: 1994–2002.
33.
Marubashi S, Gotoh K, Akita H, et al: Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg 2015; 102: 776–784.
34.
Sasaki A, Kai S, Iwashita Y, et al: Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 2005; 103: 299–306.
35.
Ahn KS, Kang KJ, Park TJ, et al: Benefit of systematic segmentectomy of the hepatocellular carcinoma: revisiting the dye injection method for various portal vein branches. Ann Surg 2013; 258: 1014–1021.
36.
Shindoh J, Mise Y, Satou S, et al: The intersegmental plane of the liver is not always flat–tricks for anatomical liver resection. Ann Surg 2010; 251: 917–922.
37.
Hata F, Hirata K, Murakami G, Mukaiya M: Identification of segments VI and VII of the liver based on the ramification patterns of the intrahepatic portal and hepatic veins. Clin Anat 1999; 12: 229–244.
38.
Fasel JH, Schenk A: Concepts for liver segment classification: neither old ones nor new ones, but a comprehensive one. J Clin Imaging Sci 2013; 3: 48.
39.
Miyata A, Ishizawa T, Tani K, et al: Reappraisal of a dye-staining technique for anatomic hepatectomy by the concomitant use of indocyanine green fluorescence imaging. J Am Coll Surg 2015; 221:e27–e36.
40.
Inoue Y, Arita J, Sakamoto T, et al: Anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging. Ann Surg 2015; 262: 105–111.
41.
Curro G, Bartolotta M, Barbera A, et al: Ultrasound-guided radiofrequency-assisted segmental liver resection: a new technique. Ann Surg 2009; 250: 229–233.
42.
Santambrogio R, Costa M, Barabino M, Opocher E: Laparoscopic radiofrequency of hepatocellular carcinoma using ultrasound-guided selective intrahepatic vascular occlusion. Surg Endosc 2008; 22: 2051–2055.
43.
Takasaki K, Kobayashi S, Tanaka S, et al: Highly anatomically systematized hepatic resection with Glissonean sheath code transection at the hepatic hilus. Int Surg 1990; 75: 73–77.
44.
Torzilli G, Makuuchi M: Ultrasound-guided finger compression in liver subsegmentectomy for hepatocellular carcinoma. Surg Endosc 2004; 18: 136–139.
45.
Torzilli G: Ultrasound-Guided Liver Surgery: An Atlas, ed 1. Milan, Springer-Verlag, 2014.
46.
Torzilli G, Procopio F, Cimino M, et al: Anatomical segmental and subsegmental resection of the liver for hepatocellular carcinoma: a new approach by means of ultrasound-guided vessel compression. Ann Surg 2010; 251: 229–235.
47.
Torzilli G, Cimino M, Del Fabbro D, et al: Anatomical resection of segment 8 by means of ultrasound-guided vessel compression. Ann Surg Oncol 2013; 20: 474.
48.
Kang TW, Lim HK, Lee MW, et al: Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation: risk factors and clinical significance. Radiology 2015; 276: 274–285.
49.
Yamashita S, Aoki T, Inoue Y, et al: Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Surgery 2015; 157: 463–472.
50.
Wakabayashi G, Cherqui D, Geller DA, et al: Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 2015; 261: 619–629.
51.
Cherqui D, Husson E, Hammoud R, et al: Laparoscopic liver resections: a feasibility study in 30 patients. Ann Surg 2000; 232: 753–762.
52.
Berardi G, Van Cleven S, Fretland ÅA, et al: Evolution of laparoscopic liver surgery from innovation to implementation to mastery: perioperative and oncologic outcomes of 2,238 patients from 4 European specialized centers. J Am Coll Surg 2017; 225: 639–649.
53.
Viganò L, Tayar C, Laurent A, Cherqui D: Laparoscopic liver resection: a systematic review. J Hepatobiliary Pancreat Surg 2009; 16: 410–421.
54.
Yoon YS, Han HS, Cho JY, Ahn KS: Total laparoscopic liver resection for hepatocellular carcinoma located in all segments of the liver. Surg Endosc 2010; 24: 1630–1637.
55.
Cheung TT, Dai WC, Tsang SH, et al: Pure laparoscopic hepatectomy versus open hepatectomy for hepatocellular Carcinoma in 110 patients with liver cirrhosis: a propensity analysis at a single center. Ann Surg 2016; 264: 612–620.
56.
Han HS, Shehta A, Ahn S, et al: Laparoscopic versus open liver resection for hepatocellular carcinoma: case-matched study with propensity score matching. J Hepatol 2015; 63: 643–650.
57.
Laurent A, Cherqui D, Lesurtel M, et al: Laparoscopic liver resection for subcapsular hepatocellular carcinoma complicating chronic liver disease. Arch Surg 2003; 138: 763–769.
58.
Kaneko H, Takagi S, Otsuka Y, et al: Laparoscopic liver resection of hepatocellular carcinoma. Am J Surg 2005; 189: 190–194.
59.
Belli G, Limongelli P, Fantini C, et al: Laparoscopic and open treatment of hepatocellular carcinoma in patients with cirrhosis. Br J Surg 2009; 96: 1041–1048.
60.
Sasaki A, Nitta H, Otsuka K, et al: Ten-year experience of totally laparoscopic liver resection in a single institution. Br J Surg 2009; 96: 274–279.
61.
Memeo R, de’Angelis N, Compagnon P, et al: Laparoscopic vs. open liver resection for hepatocellular carcinoma of cirrhotic liver: a case-control study. World J Surg 2014; 38: 2919–2926.
62.
Morise Z, Ciria R, Cherqui D, et al: Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease. J Hepatobiliary Pancreat Sci 2015; 22: 342–352.
63.
Cipriani F, Fantini C, Ratti F, et al: Laparoscopic liver resections for hepatocellular carcinoma. Can we extend the surgical indication in cirrhotic patients? Surg Endosc 2018; 32: 617–626.
64.
Parks KR, Kuo YH, Davis JM, et al: Laparoscopic versus open liver resection: a meta-analysis of long-term outcome. HPB 2014; 16: 109–118.
65.
Takahara T, Wakabayashi G, Beppu T, et al: Long-term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 2015; 22: 721–727.
66.
Laurent A, Tayar C, Andréoletti M, et al: Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2009; 16: 310–314.
67.
Yoon YI, Kim KH, Kang SH, et al: Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis. Ann Surg 2017; 265: 856–863.
68.
Machado MA, Surjan RC, Basseres T, et al: The laparoscopic Glissonian approach is safe and efficient when compared with standard laparoscopic liver resection: results of an observational study over 7 years. Surgery 2016; 160: 643–651.
69.
Figueroa R, Laurenzi A, Laurent A, Cherqui D: Perihilar glissonian approach for anatomical parenchymal sparing liver resections: technical aspects: the taping game. Ann Surg 2018; 267: 537–543.
70.
Honda G, Kurata M, Okuda Y, et al: Totally laparoscopic hepatectomy exposing the vessels around the tumor intended to secure the surgical margin. Surg Endosc 2014; 28: 1331–1332.
71.
Livraghi T, Giorgio A, Marin G, et al: Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101–108.
72.
Lencioni RA, Allgaier HP, Cioni D, et al: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235–240.
73.
Shiina S, Teratani T, Obi S, et al: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122–130.
74.
Crocetti L, de Baere T, Lencioni R: Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33: 11–17.
75.
Lencioni R, Crocetti L: Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262: 43–58.
76.
Pommergaard HC, Rostved AA, Adam R, et al: Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int 2018; 31: 531–539.
77.
Cho YK, Kim JK, Kim WT, Chung JW: Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010; 51: 1284–1290.
78.
Majno PE, Mentha G, Mazzaferro V: Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: confirming the trial that will never be, and some comments on the indications for liver resection. Hepatology 2010; 51: 1116–1118.
79.
Shiina S, Tateishi R, Arano T, et al: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569–577.
80.
Huang J, Yan L, Cheng Z, et al: A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903–912.
81.
Kim YS, Lim HK, Rhim H, et al: Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013; 58: 89–97.
82.
Mauri G, Porazzi E, Cova L, et al: Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging 2014; 5: 209–216.
83.
Solbiati L, Ierace T, Tonolini M, Cova L: Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004; 51:S19–S23.
84.
Mauri G, Cova L, De Beni S, et al: Real-time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with US: results in 295 cases. Cardiovasc Intervent Radiol 2015; 38: 143–151.
85.
Solbiati M, Passera KM, Goldberg SN, et al: A novel CT to cone-beam CT registration method enables immediate real-time intraprocedural three-dimensional assessment of ablative treatments of liver malignancies. Cardiovasc Intervent Radiol 2018, Epub ahead of print.
86.
Abdelaziz AO, Nabeel MM, Elbaz TM, et al: Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol 2015; 50: 479–484.
87.
Poggi G, Tosoratti N, Montagna B, Picchi C: Microwave ablation of hepatocellular carcinoma. World J Hepatol 2015; 7: 2578–2589.
88.
Wang X, Sofocleous CT, Erinjeri JP, et al: Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013; 36: 166–175.
89.
Chinnaratha MA, Chuang MY, Fraser RJ, et al: Percutaneous thermal ablation for primary hepatocellular carcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31: 294–301.
90.
Facciorusso A, Di Maso M, Muscatiello N: Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2016; 32: 339–344.
91.
Silk M, Tahour D, Srimathveeravalli G, et al: The state of irreversible electroporation in interventional oncology. Semin Int Radiol 2014; 31: 111–117.
92.
Cannon R, Ellis S, Hayes D, et al: Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107: 544–549.
93.
Cannon R, Ellis S, Hayes D, et al: Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107: 544–549.
94.
Wang Y, Luo Q, Li Y, et al: Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One 2014; 9:e84484.
95.
Chen MS, Li JQ, Zheng Y, et al: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321–328.
96.
Feng K, Yan J, Li X, et al: A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794–802.
97.
Fang Y, Chen W, Liang X, et al: Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 193–200.
98.
Lu MD, Kuang M, Liang LJ, et al: Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006; 86: 801–805.
99.
Kang TW, Kim JM, Rhim H, et al: Small hepatocellular carcinoma: radiofrequency ablation versus nonanatomic resection – propensity score analyses of long-term outcomes. Radiology 2015; 275: 908–919.
100.
Takayasu K, Arii S, Sakamoto M, et al: Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int 2018; 38: 484–493.
101.
Ueno S, Sakoda M, Kubo F, et al: Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg 2009; 16: 359–366.
102.
Vitale A, Peck-Radosavljevic M, Giannini EG, et al: Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol 2017; 66: 412–423.
103.
Hasegawa K, Kokudo N, Makuuchi M, et al: Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724–729.
104.
Pompili M, Saviano A, de Matthaeis N, et al: Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol 2013; 59: 89–97.
105.
Santambrogio R, Bruno S, Kluger MD, et al: Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma. Dig Liver Dis 2016; 48: 189–196.
106.
Kim GA, Shim JH, Kim MJ, et al: Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. Br J Surg 2016; 103: 126–135.
107.
Wang JH, Wang CC, Hung CH, et al: Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412–418.
108.
Ito T, Tanaka S, Iwai S, et al: Outcomes of laparoscopic hepatic resection versus percutaneous radiofrequency ablation for hepatocellular carcinoma located at the liver surface: a case-control study with propensity score matching. Hepatol Res. 2016; 46: 565–574.
109.
Liu PH, Hsu CY, Hsia CY, et al: Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤2 cm in a propensity score model. Ann Surg 2016; 263: 538–545.
110.
Miura JT, Johnston FM, Tsai S, et al: Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015; 17: 896–901.
111.
He W, Li B, Zheng Y, et al: Resection vs. ablation for alpha-fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Int 2016; 36: 1677–1687.
112.
Lee S, Kang TW, Cha DI, et al: Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes. J Hepatol 2018:pii:S0168-8278(18)30148-X.
113.
Xu XL, Liu XD, Liang M, Luo BM: Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology 2018; 287: 461–472.
114.
Li W, Zhou X, Huang Z, et al: Short-term and long-term outcomes of laparoscopic hepatectomy, microwave ablation, and open hepatectomy for small hepatocellular carcinoma: a 5-year experience in a single center. Hepatol Res 2017; 47: 650–657.
115.
Cucchetti A, Piscaglia F, Cescon M, et al: Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300–307.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.